A randomized study comparing Esomeprazole based versus rabeprazole based triple therapy for the eradication of Helicobacter pylori.

A randomized study comparing Esomeprazole based versus rabeprazole based triple therapy for the eradication of Helicobacter pylori. - A randomized study comparing Esomeprazole based versus rabeprazole based triple therapy for the eradication of Helicobacter pylori.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007550

Enrollment

220

Registered

2012-03-31

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Esomeprazole 20mg, AMPC 750mg, CAM 200mg, twice a day for 7days Rabeprazole 10mg, AMPC 750mg, CAM 200mg, twice a day for 7days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who want to receive a Helicobacter pylori infection test and to take eradication treatment if its result is positive. Patients who give a written informed consent

Exclusion criteria

Exclusion criteria: Past history of allergy for the drugs used in this study. Past history of taking eradication therapy. Past history of gastrectomy. Gastric cancer patients, pregnancy or lactation . Severe renal dysfunction ,Blood disease, Infectious Mononucleosis Patients who are disqualified for the study by their physicians

Design outcomes

Primary

Measure	Time frame
Comparison of the eradication rate of the two regimens, Esomeprazole based vs Rabeprazole based triple therapy.	—

Countries

Japan

Contacts

Public ContactTadayoshi Okimoto

Oita University Hospital Dpt. of Gastroenterology

okimoto@oita-u.ac.jp097-586-6193

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026